Targanta Therapeutics Corp (MM) (NASDAQ:TARG)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Targanta Therapeutics Corp (MM) Charts. Click Here for more Targanta Therapeutics Corp (MM) Charts.](/p.php?pid=staticchart&s=N%5ETARG&p=8&t=15)
Targanta Therapeutics Corporation (NASDAQ: TARG) today announced that
data describing oritavancin’s multiple
mechanisms of action and its concentration-dependent bactericidal
activity will be delivered at the combined annual meetings of the 48th
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
and the 46th Infectious Disease Society of
America (IDSA), taking place in Washington, DC, October 25-28, 2008.
These presentations address the mechanisms that enable oritavancin to be
active against gram-positive pathogens as shown in two Phase 3 trials,
both of which met their primary endpoints.
Presentations of data will focus on oritavancin’s:
Three mechanisms of action
Oritavancin interferes with gram-positive bacterial stasis in three
different ways. Similar to vancomycin, oritavancin binds to the
bacterial stem peptide and blocks cell wall synthesis (F1-366). However,
unlike vancomycin’s single action on the cell
wall, oritavancin attacks cell wall synthesis at two independent sites.
First, the compound directly inhibits bacterial transglycosylase, which
is the enzyme that forms the glycan backbone of the cell wall. Second,
oritavancin inhibits transpeptidase, an enzyme that cross links adjacent
glycan strands. Oritavancin’s third mechanism
of action is its ability to disrupt membrane integrity resulting in
bacterial cell death (C1-199 and C1-4182).
Bactericidal against intracellular S. aureus
Oritavancin shows greater bactericidal activity against intracellular S.
aureus than most other antibiotics used to treat gram-positive
pathogens (A-970, A-971 and A-972).
Dose-dependent bactericidal activity
Additionally, Poster C1-3737 entitled, “In
vitro Time Kill Studies of Oritavancin against
Vancomycin-Intermediate Staphylococcus aureus (VISA)”
will be presented at 10 a.m. on Tuesday, October 28, 2008.
The schedule of presentations is as follows:
DATE
TIME
TYPE
AUTHOR
TITLE
Saturday,
October 25
12:15 p.m. – 1:15 p.m.
Poster
Belley
Pretreatment of In Vitro Model Surfaces of Indwelling Devices
with Oritavancin Prevents Biofilm Formation by Staphylococcus
epidermidis (C1-198)
Poster
Domenech
Comparative Study of the Membrane Permabilization Induced by
Oritavancin (ORI) vs. Vancomycin (VAN) in Liposomes and Role of an
Acidic Phospholipid (C1-199)
Poster
Kim
Hexapeptide of Oritavancin with Damaged Aglycon Exhibits Dual Mode
of Action Against Cell-Wall Biosynthesis in Staphylococcus aureus
(F1-366)
Poster
Kim
Hydrophobic Sidechain Length Determines Conformational Heterogeneity
of Lipoglycopeptide Binding to the Cell Wall of Staphylococcus
aureus (F1-368)
Sunday,
October 26
11:15 a.m. – 12:15 p.m.
Poster
Nguyen
SCV Phenotype and Reduced Intracellular Activity of Antibiotics: A
Cause for Persistent Staphylococcal Infection? (A-970)
Poster
Baudoux
Intracellular Activity of Oritavancin against MSSA, MRSA and VISA
Strains in a Model of Human Macrophages (A-971)
Poster
Nguyen
Subcellular Localization of S. aureus Small Colony Variant
(SCV) versus its Normal Phenotype (NP) Counterpart in a Model of
Calu-3 Airway Epithelial Cells: Impact on the Intracellular Activity
of Oritavancin, Gentamicin, Oxacillin and Moxifloxacin (A-972)
Tuesday,
October 28
8:30 a.m. – 8:45 a.m.
Slides
Belley
Efficacy of Oritavancin against In vitro Biofilms Derived
from Clinical Isolates of Staphylococcus epidermidis (C1-3711)
10:00 a.m. – 10:15 a.m.
Slides
McKay
In vitro Time Kill Studies of Oritavancin against
Vancomycin-Intermediate Staphylococcus aureus (VISA) (C1-3717)
4:00 p.m. – 4:15 p.m.
Slides
McKay
Oritavancin Disrupts Membrane Integrity to Effect Cell Killing of
Vancomycin (VAN)-Nonsusceptible Staphylococcus aureus (SA)
and VAN-resistant Enterococcus faecium (VRE) (C1-4182)
About Oritavancin
Oritavancin is a novel semi-synthetic lipoglycopeptide antibiotic
candidate with potent bactericidal (killing) activity against a broad
spectrum of gram-positive bacteria. In its intravenous (IV) formulation,
the product candidate has been tested in over 2,400 individuals and has
completed two Phase 3 studies for the treatment of complicated skin and
skin structure infections (cSSSI) in which the primary endpoints were
met. Targanta submitted a New Drug Application (NDA) to the U.S. Food
and Drug Administration (FDA) in February 2008 seeking to commercialize
oritavancin for the treatment of cSSSI; the FDA accepted the NDA
submission for standard review, establishing an action date of December
8, 2008. Targanta’s Marketing Authorization
Application (MAA) for oritavancin was accepted for review by the
European Medicines Agency (EMEA) in June 2008. Targanta is also
developing an oral version of oritavancin for the possible treatment of Clostridium
difficile.
About Targanta Therapeutics
Targanta Therapeutics Corporation (Nasdaq: TARG) is a biopharmaceutical
company focused on developing and commercializing innovative antibiotics
to treat serious infections in the hospital and other institutional
settings. The Company’s pipeline includes an
intravenous version of oritavancin, a semi-synthetic lipoglycopeptide
antibiotic currently awaiting U.S. and EU regulatory approval, and, a
program to develop an oral version of oritavancin for the treatment of Clostridium
difficile. The Company has operations in Cambridge, MA,
Indianapolis, IN, and Montreal, Québec,
Canada. For more information on Targanta, visit www.targanta.com.
Safe Harbor Statement
This press release contains “forward-looking
statements” that are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. These are statements that are predictive in nature, that depend
upon or refer to future events or conditions or that include words such
as “may,” "will,"
"expects," "projects," "anticipates," "estimates," "believes,"
"intends," "plans," "should," "seeks," “hope”
and similar expressions. Forward-looking statements involve known and
unknown risks and uncertainties that may cause actual future results to
differ materially from those projected or contemplated in the
forward-looking statements. Forward-looking statements may be
significantly impacted by certain risks and uncertainties described in
Targanta’s filings with the Securities and
Exchange Commission. The risks and uncertainties referred to above
include, but are not limited to, risks related to Targanta’s
dependence on the success of oritavancin; delays in obtaining or a
failure to obtain regulatory approval for Targanta’s
product candidates; failure of any approved product to achieve
significant commercial acceptance in the medical community or receive
reimbursement by third-party payors; unfavorable clinical trial results;
failure to maintain and protect Targanta’s
intellectual property assets and to avoid infringing the intellectual
property rights of others; competition from other pharmaceutical or
biotechnology companies; Targanta’s potential
inability to initiate and complete pre-clinical studies and clinical
trials for its product candidates; the possibility that results of
pre-clinical studies are not necessarily predictive of clinical trial
results; and those other risks factors that are described more fully in
the Company’s filings with the Securities and
Exchange Commission. Targanta does not undertake any obligation to
update any of these forward-looking statements to reflect a change in
its views or events or circumstances that occur after the date of this
release.